1454585-22-8

Basic information

• Product Name: 2-chloro-N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-9H-purin-6-amine
• Synonyms: 2-chloro-N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-9H-purin-6-amine
• CAS NO: 1454585-22-8
• Molecular Weight: 429.791
• Mol File: 1454585-22-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-chloro-N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-9H-purin-6-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-9H-purin-6-amine(1454585-22-8)
• EPA Substance Registry System: 2-chloro-N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-9H-purin-6-amine(1454585-22-8)

Safety Data

• Hazardous Substances Data: 1454585-22-8(Hazardous Substances Data)

Upstream product

• 1446513-80-9 2,6-dichloro-9-(3-fluorophenyl)-9H-purine 
• 768-35-4 3-fluorophenylboronic acid 
• 1446513-83-2 (4,5-difluoro-1H-benzo[d]imidazol-2-yl)methanamine hydrochloride 
• 1201597-26-3 tert-butyl (4,5-difluoro-1H-benzo[d]imidazol-2-yl)methylcarbamate 
• 5451-40-1 2,6 dichloropurine 
• 153505-39-6 3,4-difluoro-1,2-phenylenediamine 

Downstream Products

• 1454585-06-8 N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-2-morpholino-9H-purin-6-amine 

Relevant articles and documents

Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer

Casein kinase 1δ/ε have been identified as promising therapeutic target for oncology application, including breast and brain cancer. Here, we described our continued efforts in optimization of a lead series of purine scaffold inhibitors that led to identification of two new CK1δ/ε inhibitors 17 and 28 displaying low nanomolar values in antiproliferative assays against the human MDA-MB-231 triple negative breast cancer cell line and have physical, in vitro and in vivo pharmacokinetic properties suitable for use in proof of principle animal xenograft studies against human cancers.

WEE1 DEGRADATION INHIBITORS

The invention provides compounds that inhibit the degradation of Weel. The compounds of the present invention are generally N-((1H-benzo[d]imidazol-2- yl)methyl)-9H-purin-6-amines. Compounds of the invention can be used for treatment of malconditions in p